Private company
Diamyd Medical
Logo: https://www.diamyd.com/Default.aspx, Non-free logo, via Wikipedia4
Swedish biotechnology company
Diamyd Medical AB (Stockholm NASDAQ, First North) is a small biotechnology company headquartered in Stockholm, Sweden that focuses on immune modifying therapies for type-1 diabetes. The company's investigational drug retogatein is based on a recombinant form of GAD65, one of two human glutamate decarboxylase gene products. The company is headquartered in Stockholm, and maintains a "biomanufacturing" facility in Umeå which utilizes bacuolavirus-mediated protein expression.2 Wikipedia text CC BY-SA 4.0
Last updated Oct 21, 2026.
Overview
- HeadquartersStockholm1
- Websitewww.diamyd.com/Default.aspx
- Legal formAktiebolag3
- LEI5493003NP2HNQDEKB8043
- StatusActive3
- LEI statusIssued and current3
- Registered addressBOX 7349, 103 90 Stockholm, Sweden3
- Registered withSwedish Companies Registration Office, 556242-37973
See how the biggest companies compare on our leaderboards
Diamyd Medical AB (Stockholm NASDAQ, First North) is a small biotechnology company headquartered in Stockholm, Sweden that focuses on immune modifying therapies for type-1 diabetes. The company's investigational drug retogatein is based on a recombinant form of GAD65, one of two human glutamate decarboxylase gene products.2
Timeline
- 1996Founded Founded1
Links
- Websitewww.diamyd.com/Default.aspx1
- WikipediaDiamyd Medical
- WikidataQ5271033
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1WikidataDiamyd Medical on Wikidata
- 2WikipediaDiamyd Medical on Wikipedia
- 3
- 4